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I n 1958, Albert Kligman published three remarkable papers on the subject of poison ivy dermatitis and its prevehtion (1-3J (fig 1) that established a benchmark for this modest, if annoying aspect of the clinical practice of dermatology. This review and tribute will attempt to place his contribu­
tions in perspective with advances that have occurred in the past 
quarter century. The paper is divided into scientific sections that 
subserve the observations made by Kligman. 
BOTANY 
Some may know that Dr. Kligman was trained in botany before 
getting his medical degree and that he was, in fact, a world au­
thority on mushrooms, writing a definitive book on the subject 
that made him a consultant to the mushroom industry for many 
years. However, he was less well informed about the poison 
ivy/oak family of plants, and used the misnomer "Rhus" in the 
title of his papers. This no doubt followed the convention of 
earlier workers in the field and fit his penchant for brisk, Hem­
ingway-like articulation. A serious botanist fully committed to 
this problem, William Gillis, investigated the distribution and 
taxonomy of these weeds and related plants during the 1960s and 
70s, and corrected the misconceptions about the family and genus 
of these plants [4,5]. Poison ivy is correctly called Toxicodendron 
radicans, and poison oak, Toxicodendron diversilobum; whereas poi­
son sumac is labeled Toxicodendron vernix. Obviously, these bo­
tanical tongue twisters are too much for any but an afficionado 
of the subject, so that most papers now refer to poison ivy/oak 
dermatitis. 
Kligman [1] refers to the most common allergenic plants that 
cross-react with poison ivy-namely the Japanese lacquer tree; 
the marking nut of Southeast Asia; the mango rind, which ac­
counts for the "florida Grin;" and cashew nutshell oil, responsible 
for swizzel-stick dermatitis and most recently an epidemic of 
dermatitis in western Pennsylvania caused by Boy Scouts selling 
improperly prepared cashew nuts [6] . 
As Gillis [5] showed, although poison oak and poison ivy prob­
ably originated in North America, there seems to be a connection 
to the oriental cross-reacting plants, perhaps via the northern land 
bridge of ancient times. Also, there is increasing evidence that 
related plants have appeared in South America in great profusion 
so that recognition of the plants containing cross-reacting aller­
gens has increased remarkably [7,8]. In addition, urusi (poison 
ivy) dermatitis has spread to the general population inJapan (Ep­
stein, unpublished observation). The plant also has made its ap-
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pearance in Europe as an ornamental flower, a vine to shore up 
the dikes in the Netherlands, and a wild plant in france and 
Germany responsible for an occasional bout of dermatitis [9J. 
As Kligman f1 J pointed out, "Taxonomic confusion stems from 
the morphologic variability of the plant. " However, because of 
the yeoman work of Gillis [4,5], it is clear that poison ivy grows 
mainly east of the Rocky Mountains and poison oak on the west­
ern side. In Canada, they tend to disappear as one travels north 
and the plants have not been reported in Alaska. On the other 
hand, in Texas, where the Rockies disintegrate, the two plants 
tend to intermingle. Perhaps the most important practical points 
are: (1) despite being botanically separable, the clinical reactions 
to poison oak and poison ivy are the same, and sensitivity to one 
confers equal sensitivity to the other; and (2) the appearance of 
these plants is so variable that the weed is distinctive only for a 
given region. Thus, poison oak from Northern California does 
not resemble poison oak in Southern California. 
CHEMISTRY 
Kligman's advantage over previous workers was that Dawson 
and his group at Columbia had chemically analyzed poison ivy 
carefully and demonstrated that it contains saturated and unsat­
urated urushiol with up to 3 double bonds in the carbon side 
chain attached to position 3 on the catechol ring [10,11] . In ad­
dition, Dawson's group had synthesized the saturated compo­
nent, 3-n-pentadecylcatechol (PDq [12], which was used by 
Kligman in most of his immunobiologic studies. 
Since then, continuing advances in- sophisticated technology, 
including gas/liquid chromatography and mass spectrometry [13], 
and further modifications [14] have allowed innumerable analyses 
of the chemicals in these weeds. The upshot of all this is that, in 
general, poison ivy has a CI5 side chain; poison oak, a CI7 side 
chain; and poison sumac, a CI3 side chain. In the case of poison 
oak, the side chain is usually unsaturated, without a trace of 
heptadecylcatechol, even though it is easily synthesized [15]. Also, 
it has been confirmed that the side chain determines the specificity 
of the molecule [16,17], whereas initial binding to tissue proteins 
depends upon converting the hydroxyl groups at positions 1 and 
2 on the ring of 3-n-alkylcatechol to quinones [17-19J (fig 2), so 
that covalent bonds can be formed. Further analysis revealed that 
ring positions 4, 5, and 6 are free and available for nucleophilic 
attack. By selective methylation at the different reactive positions 
in the catechol ring, regiospecificity in the reactivity of urushiol 
was demonstrated [15] . Thus, the 6 position reacted only with 
sulfhydryl groups, whereas the 5 position reacted only with amino 
groups [15]. These binding preferences on the ring were found 
to determine the presence or absence of contact sensitization in 
animal experiments [19]. Thus, continuing analysis of the urushiol 
molecule has revealed some subtle binding characteristics that 
explain sensitization and can be used to produce desensitization 
or tolerance (see below). 
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Figure 1. Poison ivy picker'of Pennypack Park. Picking poison-filled 
leaves. Dr. Kligman collects test materiaL 
BIOLOGY 
This section deals with the biologic effects on people of exposure 
to these poisonous plants, and here Kligman [1] is masterfuL With 
the newer knowledge about the chemical and physical nature of 
urushiol, he was able to debunk many of the long-standing myths 
that crowd lay perception of poison oaklivy dermatitis, and ex­
plain the numerous cryptic observations of his predecessors [20-23]. 
This is the historically classic section of the paper, which should 
be reread in the original by all young practitioners who wish to 
tell their patients the truth about this subject. A minor point comes 
up as to where urushiol is distributed in the plant. There is agree­
ment that it is found in the resin canals that course through the 
roots, vines, and leaves. Whether or not it is distributed into the 
flowers and berries is less certain. Rodriguez [24], a phytochemist 
interested in plant allergens, believes that the point has not been 
rigorously tested. It is well known, however, that the honey 
produced by bees who feed on poison ivy/oak does not appear 
to contain allergenically active urushioL Parenthetically, the honey 
is quite bitter. 
EPIDEMIOLOGY 
The earlier observations and Kligman's findings suggested that 
approximately 50% of the adult population in the United States 
are clinically sensitive to poison ivy/oak, and this has been borne 
out by subsequent studies [25]. The observation that blacks appear 
less reactive than whites, implying they are less readily sensitized 
by contact allergens, has not been totally supported by more 
recent conflicting reports [26,27), but clinical experience still in­
sists that blacks are not as likely as whites to complain of acute 
allergic poison ivy dermatitis. An interesting controversy arose 
when Epstein and Clair borne reported that orientals born in Asia 
were less likely than their American compatriots to develop poi­
son oak dermatitis when both groups worked in the United States 
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Figure 2. Urushiol in skin is converted in the presence of oxygen to a 
highly reactive quinone, which then becomes susceptible to regiospecific 
nucleophilic attack of the ring structure at sites 4. 5, and 6. 
[28). This suggestion could hold significant meaning for so-called 
"natural tolerance" and implies that exposure early in life to cross­
reacting, less allergenic chemicals in fruits and plants might induce 
a state of tolerance. Our studies with urushiol patch tests in new 
arrivals from the Orient and South America, unfortunately, gave 
many positive responses and did not support their contention 
[291-
Regarding the persistence of sensitivity over time, Kligman [1] 
noted that "the incidence and intensity of poison ivy, usually 
acquired in childhood, appear to decline proportionally with age." 
Subsequent studies [30] showed that infants and young children 
below the age of 5 years are less readily sensitized to PDC than 
older children. This partially explains why the peak frequency of 
contact sensitivity to these weeds occurs between the ages of 8 
and 14 years. It should be noted, however, that the actual level 
of skin sensitivity of an individual, as one grows older, is not so 
clearly known; so that depending upon activity and exposure, a 
person may become more or less reactive with increasing age 
[31]. In addition, the clinical finding that contact sensitivity to 
poison ivy/oak runs in families has been supported by experi­
mental studies, which indicate that if both parents are contact 
sensitive, there is an approximately 80% chance that the children 
will also become sensitized [32]. 
IMMUNOLOGY 
This portion of Kligman's treatise [1] is dated. The revolution in 
immunologic technology had not yet begun. Furious disputations 
were being waged among immunologists about whether lym­
phocytes could indeed make antibodies. Concepts about cell me­
diated immunity (CMI) lagged even further behind. A history of 
the research of CMI at that time is chronicled by Chase [33]. In 
total, the studies of poison ivy/oak, although confirmatory, have 
contributed relatively little to our basic understanding of the in­
duction of CM!. Some careful and elegant immunologic studies 
in guinea pigs [34] sharply focused attention on the immuno­
chemical nature of the antigenic determinants of urushiol [16,17]. 
An early study of passive transfer with leukocytes from poison 
ivy-sensitive donors proved to be the only situation in which 
positive transfers to a contact allergen in humans could be effected 
without repeated prior exposure of the recipients to the simple 
chemical [35-37]. Experimental studies of poison ivy did not 
materially affect the concept of antigen presentation by dendritic 
cells in the epidermis [38-40], nor did they deal with suppressor 
factors that occur during the induction of tolerance [41-;-43), but 
investigations in guinea pigs and mice have clearly shown that 
tolerance can be induced in naive animals by altering the route 
of exposure or by use of modified but related chemicals 
[18, 19.44-48]. 
Baer's group [45] made the interesting observation that ana­
logues substituted in the 6 position on the catechol ring of PDC 
could induce immunologic tolerance, and some of these were 
very poor sensitizers. This work has been extended to include 
analogues with substitutions at positions 4, 5, and/or 6 in mice 
[48], and more recently confirmed in guinea pigs [49]. Kligman 
had tried to prevent sensitization in children by daily feedings of 
PDC, but failed [1]. On the other hand, we were successful in 
producing partial, persistent tolerance in young children by in-
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tramuscular injection of small amounts of purified urushiol [50]. 
Experimental studies of the past 25 years have indicated the fea­
sibility of preventing sensitization to poison ivy/oak by injecting 
young, naive children with urushiol or potentially less toxic an­
alogues. 
SYSTEMIC PROPHYLAXIS 
This is the one section where clinical observation manifestly fore­
shadowed scientific investigation. It had long been rumored that 
American Indians were protected against the undesirable effects 
of poison ivy/oak because they ingested the leaves of these �eeds 
[51]. During the first years of the 20th century, several enthusiasts 
offered up a variety of extracts and concoctions as pabulum [2,3]. 
Shelmire and Howell, stalwarts of the clinical scene, supplied the 
best studies to support this rather vague idea [52,53], but it was 
left for Kligman to sift through the data and misinformation and 
chart a true course. He fed volunteers large doses of PDC over 
a long time and showed that this achieved a modest but definite 
reduction in patch-test reactivity in most subjects [2]. He also 
found that a similar regimen with cashew nutshell oil (cardol) 
was equally effective [3]. His control studies proved almost as 
meaningful. Persons on placebos reported clinical protection from 
poison ivy dermatitis, even though their patch-test reactivity did 
not change [2]. Unhappily, the uncertainty of the concept, the 
meager results of hyposensitization and Kligman's contumelious 
comments led practicing immunologists of the time to deny any 
scientific merit to the clinical findings. Undoubtedly this lack of 
official status created a vacuum and encouraged greedy and mis­
guided companies to continue offering glorified placebos [51]. 
Further investigation [25,54,55], including a carefully controlled 
double-blind study [55], have confirmed Kligman's observations, 
which in the parlance of modem immunology are now considered 
a form of acquired tolerance, and are ascribed to the production 
of suppressor T cells and possibly other suppressor factors by the 
oral ingestion of purified urushiol [43,51]. The price for protec­
tion, however, is high in terms of untoward reactions such as 
pruritus ani, general itching, urticaria, and other rashes during 
the procedure using purified extracts [25,51,55], so that patients 
q�it wi�� the comment that the "treatment is worse than the 
disease. 
This difficulty led Watson and colleagues to investigate diace­
tylated urushiol molecules as an analogue that might induce hy­
posensitization without the undesirable cutaneous side effects [56]. 
Her findings encouraged clinical trials with a so-called "blocked 
PDC," but several studies indicated that, although side effects 
were reduced, measurable hyposensitization by patch testing with 
dilutions of urushiol did not occur to the same degree as after 
ingestion of purified urushiol, and the product was withdrawn 
from clinical trials [57]. Other analogues with proven activity in 
animal models [19,47,48] undoubtedly will be considered for 
commercial development in humans. In addition, the Bureau of 
Biologics of the Food and Drug Administration proposed reg­
ulations in Federal Register Oanuary 23, 1985 and August 9, 1985) 
to remove from the market all poison ivy/oak preparations that 
contain low doses of urushiol or offer short courses of prophy­
lactic treatment, especially by the intramuscular route. In effect, 
this leaves only the high-potency, but potentially toxic oral prep­
arations available. Physicians wishing to use these oral agents need 
to monitor their patients closely, especially in the beginning, 
because the dose given must be tailored to the patient's tolerance. 
Before leaving this topic, we should consider the possibility of 
inducing renal damage by ingestion of urushiol. Abramowicz 
repeatedly notes this in his Medical Letter reviews [58], citing the 
one case seen at the University of California at San Francisco, 
where immune complex nephrosis occurred with circulating an­
tibodies to urushiol [59]. Kligman [1] reviewed the suspected cases 
of his time and concluded that the evidence did not rule out the 
"more probable explanation-that the glomerulonephritis is a 
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consequence of secondary bacterial infection." The patient with 
immune complex nephrosis seen by us likely developed the dis­
ease from repeated natural bouts of poison oak dermatitis rather 
than the 2 drops of dilute poison oak extract that he drank [59]. 
Furthermore, considering the large amounts of extract given over 
the years, this must be a very rare complication of the hyposen­
sitization procedure [51]. 
PHARMACOTHERAPY 
Despite a crescendo of activity and interest in pharmacology re­
lated to therapeutics, no specific treatment for allergic contact 
dermatitis has yet been discovered. Therapy remains empirical, 
and many questionable products vie for a slice of a moderately 
sized consumer market. As Kligman [1] found to his dismay and 
frustration, no topical product tested "influenced the course of 
acute poison ivy dermatitis when compared with standard, bland 
dermatologic treatment." Repeated and unpublished trials since 
then have affirmed the lack of activity of innumerable prepara­
tions, highly touted by their purveyors (Epstein, unpublished 
data). The single advance in topical therapy has been the devel­
opment of high-potency fluorinated corticosteroids in a gel or 
optimized vehicle. Applied during the earliest stages of the rash, 
when the skin is red and not yet blistered, they materially decrease 
further evolution of dermatitis and prevent apparent spread of the 
disease. These preparations, however, can only be used in limited 
areas because of their high potency and the real possibility of 
systemic effects if used on large areas of the body. Systemic 
corticosteroids and adrenocorticotropic hormone had just become 
available for clinical use, and their magical effects on severe acute 
poison ivy dermatitis were well described by Kligman [1]. What 
has transpired since then is a running argument as to whether 
one should give moderate doses of systemic corticosteroids over 
10 days to 2 weeks or single large doses at the onset of dermatitis 
to avoid a continued reaction [60]. 
PREVENTION 
Preventive medicine has captured the public imagination and is 
reputed to be the central theme for reducing medical costs into 
the next century. It has long been a serious consideration in the 
case of poison ivy/oak dermatitis. Kligman investigated this issue 
in some detail [1]. Under experimental circumstances, he showed 
that washing off applied urushiol with water was effective for 
about 30 min if a person was only moderately sensitive; if they 
were highly sensitive it was not possible to remove sufficient 
chemical with water to prevent a severe reaction. Clinical ex­
perience has shown that, in moderately sensitive persons, washing 
liberally with water for up to 2 h after exposure seems to reduce 
the degree of reactivity. Also, experiments since then have dem­
onstrated that the use of solvents such as acetone, alcohol, or 
xylene can effectively remove active allergen from the skin for at 
least 30 min after application (Epstein, unpublished observation), 
so that organic solvents potentially could be useful when a person 
leaves an area of high exposure to these weeds. 
Kligman [1] experimented with barrier creams and de toxicants 
and found them disappointing. However, it is known that a large 
number of substances, including albumin [15], silica, aluminum 
salts can bind avidly to urushiol, and experiments in humans have 
shown that topical applications of these preparations can reduce 
but not totally prevent experimental poison oak/ivy dermatitis 
in moderately sensitive persons [61]. In that series of experiments, 
the most active binding agent was an activated clay, Tixogel 
(United Catalysts, Inc. , Louisville, Kentucky), which is com­
monly found in many spray-on preparations. Its application to 
skin in a double-blind study indicated that it is effective in re­
ducing reactivity for up to 24 h after application [61]. Along the 
same vein, Orchard and coworkers [62] have reported that poly­
oxypropyleneamine salts of linoleic acid dimer, when applied 
topically, completely prevented experimental poison oak der-
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matitis for up to 24 h. Whether these preparations will have 
practical value in field trials remains to be determined. 
CONCLUSION 
This review emphasizes the several areas of science that relate to 
poison ivy/oak sensitivity in humans. In the past quarter century 
the botanical aspects have been well studied and it is apparent 
that a continuing recognition of cross-reacting plant allergens, 
particularly from South America, is in the offing. The biology 
has been welI described; yet there is a recurring need to instruct 
laymen and physicians alike so as to reduce morbidity from ex­
posure to these weeds. The chemistry and especially immuno­
chemistry have been deeply plumbed and integrated with the 
rapid advances in understanding of the basic science of cell-me­
diated immunity, so that strategies can now be planned to turn 
the thrust of immunologic exposure to urushiol from hypersen­
sitivity to one of immune tolerance. Perhaps a modern "vaccine" 
will emerge from these investigative forays. Pharmacotherapy 
and preventive medicine have attracted some interest, but ad­
vances lag behind the other, better defmed sciences. "The narrow 
path twists ever upward past lands of vast deep experience until 
through the majestic portals he passes into immortality." (Anon­
ymous, circa 1985) 
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